EP2794875B1 - Modifizierte leichte enterokinasekette - Google Patents

Modifizierte leichte enterokinasekette Download PDF

Info

Publication number
EP2794875B1
EP2794875B1 EP12816050.4A EP12816050A EP2794875B1 EP 2794875 B1 EP2794875 B1 EP 2794875B1 EP 12816050 A EP12816050 A EP 12816050A EP 2794875 B1 EP2794875 B1 EP 2794875B1
Authority
EP
European Patent Office
Prior art keywords
light chain
analogue
enterokinase light
enterokinase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12816050.4A
Other languages
English (en)
French (fr)
Other versions
EP2794875A1 (de
Inventor
Helle Fabricius WÖLDICKE
Xujia Zhang
Yun Liu
Weiwei TONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP2794875A1 publication Critical patent/EP2794875A1/de
Application granted granted Critical
Publication of EP2794875B1 publication Critical patent/EP2794875B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21009—Enteropeptidase (3.4.21.9), i.e. enterokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Definitions

  • the present invention is related to novel mammalian enterokinase analogues, methods of making such and the use of said mammalian enterokinase analogues for cleaving proteins having an enterokinase cleavage site.
  • the serine protease enterokinase in short enterokinase or EK
  • enteropeptidase is a heterodimeric glycoprotein, a mammalian enzyme catalyzing the conversion of trypsinogen into active trypsin.
  • Enterokinase has preference for the substrate sequence Asp-Asp-Asp-Asp-Lys ((Asp) 4 -Lys, DDDDK), where it selectively cleaves after lysine.
  • Enterokinase isolated from bovine duodenal mucosa exhibits a molecular weight (MW) of 150,000 and a carbohydrate content of 35 percent.
  • the enzyme is comprised of a heavy chain (MW ⁇ 115,000) and a disulfide-linked light chain (MW ⁇ 35,000) ( Liepnieks et al., J. Biol. Chem., 254(5): 1677-1683 (1979 )).
  • the function of the heavy chain is to anchor the enzyme to the mucosal membrane.
  • the light chain acts as the catalytic subunit.
  • Tan et al (Protein, expression and purification, academic press, San Diego, CA, vol. 56, no. 1, 3 October 2007 (2007-10-03), pages 40-47 ) discloses purification and refolding optimization of recombinant bovine enterokinase light chain overexpressed in Escherichia coli.
  • CN1470634 discloses enterpeptidase light chain variant with high activity and high stability.
  • E.coli In E.coli many mammalian proteins are expressed as fusion proteins, which have to be cleaved to release the mature, active protein. For that purpose a processing enzyme is needed, preferably one which cleaves directly at the junction leaving no extra amino acids on the product. Enterokinase is such an enzyme, and much effort has been made to establish a recombinant process to obtain enterokinase or enterokinase analogues in E.coli. However, the results so far have been rather poor: Available commercial products are expensive and of low specific activity, due to inefficient renaturation of precipitated EK or inefficient secretion of soluble EK.
  • a process in E.coli aiming at a soluble EK product leads to a mixture of soluble and insoluble protein, requiring 2 routes of purification, expensive affinity columns and low yields altogether.
  • the EK has to be produced as insoluble material in inclusion bodies. They are easy to isolate but challenging to renature in satisfactory yields, due to possible aggregation of the protein.
  • An object of the invention is to obtain a mammalian enterokinase analogue with improved properties.
  • the present invention is related to mammalian enterokinase analogues mutated in appropriate sites.
  • One or more substitutions of an enterokinase analogue of the invention may e.g. be from hydrophobic to hydrophilic, charged amino acids relative to the amino acids in the parent (wild type) mammalian enterokinase.
  • a bovine enterokinase light chain analogue which comprises an amino acid sequence set forth in SEQ ID NO: 1, wherein said analogue comprises substitutions C112A, L134K and I135K, said analogue comprises less than 10 amino acid modifications relative to SEQ ID NO: 1, and said analogue has enterokinase protease activity.
  • the invention is also related to a method for obtaining improved solubility in a renaturation process of an enterokinase light chain analogue comprising the step of mutating hydrophobic amino acids of wild type bovine enterokinase light chain to hydrophilic amino acids and optionally mutating other amino acids of wild type bovine enterokinase light chain, wherein the hydrophobic amino acids subject to mutation are present on the surface of folded wild type bovine enterokinase light chain, said analogue comprises substitutions C112A, L134K and I135K, said analogue comprises less than 10 amino acid modifications relative to SEQ ID NO: 1, and said analogue has enterokinase protease activity.
  • the invention provides an improved production process for obtaining mammalian enterokinase analogues. Also or alternatively, in a second aspect, the invention provides an improved production process resulting in improved production yield.
  • the method for production of a bovine enterokinase light chain analogue comprises the steps:
  • the invention provides a method for recombinantly producing a peptide or protein in a bacterial or yeast host cell.
  • the method comprises:
  • the invention may also solve further problems that will be apparent from the disclosure of the exemplary embodiments.
  • the present invention is related to mammalian enterokinase analogues mutated in appropriate sites.
  • One or more substitutions of an enterokinase analogue of the invention may e.g. be from hydrophobic to hydrophilic, charged amino acids relative to the amino acids in the parent (wild type) mammalian enterokinase.
  • one or more substitutions of a mammalian enterokinase analogue of the invention is from hydrophobic to hydrophilic, charged amino acids relative to the amino acids in wild type bovine enterokinase.
  • the hydrophobic amino acids subject to mutation are present on the surface of folded wild type mammalian enterokinase light chain such as folded wild type bovine enterokinase light chain.
  • the wild type bovine enterokinase light chain generally exhibits good activity in the presence of various detergents and denaturants over a wide pH range (4.5-9.5) and temperature range (4-45 °C). Therefore, the enterokinase light chain as a powerful tool has been used in biotechnology for the in vitro cleavage of fusion proteins.
  • the mammalian enterokinase analogue is a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue.
  • the mammalian enterokinase analogue is a bovine enterokinase light chain analogue.
  • the bovine light chain analogue comprises substitution(s) in position 134 and/or position 135.
  • the bovine enterokinase light chain analogue comprises substitutions in positions 112, 134 and/or 135.
  • the bovine enterokinase light chain analogue comprises at least two substitutions.
  • the bovine enterokinase light chain analogue comprises at least three substitutions. In one aspect the bovine enterokinase light chain analogue comprises substitutions in positions 112, 134 and 135. In one aspect the bovine enterokinase light chain analogue comprises the substitutions C112A, L134K and I135K.
  • Novel bovine enterokinase light chain analogues include those having the primary structural conformation (i. e., amino acid sequence) of the light chain of wild type bovine enterokinase.
  • the light chain of wild type bovine enterokinase has the sequence substantially as set forth in SEQ ID NO:1.
  • bovine enterokinase light chain analogues of the invention have enterokinase protease activity.
  • Antibodies to such proteases are also available.
  • the bovine enterokinase light chain analogue described by the present invention maintains enterokinase wild type protease activity for use as a restriction proteases to specifically cleave fusion proteins.
  • bovine enterokinase as used herein means the bovine enterokinase enzyme whose structure and properties are well-known. Mammalian enterokinases are carbohydrate containing heterodimers with a heavy chain of 650-800 amino acids and a catalytic light chain of around 235 amino acids and an overall homology of 75-80% ( Liepniecks et al., J. Biol. Chem. 254 , 1677 (1979 ), Matsushima et al., J.Biol. Chem. 269 (31), 19976 (1994 ), Kitamoto et al., Biochemistry 34, 4562 (1995 ) for bovine, porcine and human enterokinase, respectively).
  • bovine enterokinase light chain means the light chain of bovine enterokinase having 4 disulphide bridges.
  • the bovine enterokinase light chain is e.g. described in LaVallie et al, above.
  • the term "surface" in connection with amino acids present on the surface of folded wild type bovine enterokinase light chain means amino acids identified as present on the surface of the folded wild type bovine enterokinase light chain on a 3D structure as e.g. described in Mod Base P 98072.
  • An enterokinase light chain according to the invention is herein to be understood as bovine enterokinase light chain or an enterokinase light chain from another species such as porcine or human enterokinase light chain.
  • enterokinase light chain peptide means a peptide which is either bovine enterokinase light chain or an analog or a derivative thereof with enterokinase activity.
  • enterokinase activity means the capability of cleaving peptide or protein substrates at a specific site; for protein substrates, this is generally following the sequence (Asp) 4 -Lys, or a similar sequence such as those described in Light et al., Anal. Biochem. 106: 199(1980 ); (a cluster of negatively charged amino acids followed by a positively charged amino acid).
  • such activity is measured by activation of trypsinogen by cleaving the N-terminal propeptide (containing (Asp) 4 -Lys) with the enterokinase or enterokinase analogue and subsequently assaying the amount of active trypsin generated using tosyl-arginine-methylester (TAME).
  • trypsinogen by cleaving the N-terminal propeptide (containing (Asp) 4 -Lys) with the enterokinase or enterokinase analogue and subsequently assaying the amount of active trypsin generated using tosyl-arginine-methylester (TAME).
  • enterokinase activity can be measured directly by incubating the enzyme with the peptide substrate Gly (Asp) 4 -Lys-ss-naphthylamide and measuring the increase in fluorescence (excitation at 337 nm, emission at 420 nm) generated by cleavage and release of the ss-NA (ss-naphthylamide) moiety.
  • Gly (Asp) 4 -Lys-ss-naphthylamide the peptide substrate Gly (Asp) 4 -Lys-ss-naphthylamide and measuring the increase in fluorescence (excitation at 337 nm, emission at 420 nm) generated by cleavage and release of the ss-NA (ss-naphthylamide) moiety.
  • Bovine enterokinase is also active on some trypsin substrates like TAME and BAEE (benzyl-arginine
  • wild type enterokinase light chain as used herein is intended to mean an enterokinase light chain before any substitutions according to the invention have been applied thereto.
  • enterokinase light chain analogue or "bovine enterokinase light chain analogue” as used herein means a modified bovine enterokinase light chain wherein one or more amino acid residues of the enterokinase light chain have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the enterokinase light chain and/or wherein one or more amino acid residues have been added and/or inserted to the enterokinase light chain.
  • an enterokinase light chain analogue comprises less than 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to bovine enterokinase light chain, alternatively less than 9, 8, 7, 6, 5, 4, 3or 2 modifications relative to bovine enterokinase light chain.
  • an enterokinase light chain analogue comprises 5 amino acid modifications, in one aspect 4 amino acid modifications, in one aspect 3 amino acid modifications, in one aspect 2 amino acid modifications and in one aspect 1 amino acid modification relative to bovine enterokinase light chain.
  • Modifications in the enterokinase molecule light chain are denoted stating the position and the one or three letter code for the amino acid residue substituting the native amino acid residue.
  • terms like 134K and 135K designates that the amino acid in position 134 and 135, respectively, is K.
  • the corresponding expressions are 134Lys and 135Lys, respectively.
  • 112Ala, 134Lys, 135Lys bovine enterokinase light chain is an analogue of bovine enterokinase light chain where the amino acid in position 112 is substituted with alanine, the amino acid in position 134 is substituted with lysine and the amino acid in position 135 is substituted with lysine.
  • amino acid residue is an amino acid from which, formally, a hydroxy group has been removed from a carboxy group and/or from which, formally, a hydrogen atom has been removed from an amino group.
  • bovine enterokinase light chain analogues are such wherein Leu in position 134 is substituted with Lys or another charged amino acid, at position 135 where Ile is substituted with Lys or another charged amino acid.
  • Cys in position 112 may be substituted with a number of amino acids including Ala and Ser.
  • bovine enterokinase light chain analogues include, without limitation: 134Lys bovine enterokinase light chain; 135Lys bovine enterokinase light chain; 134Lys,135Lys bovine enterokinase light chain; 112Ala, 134Lys, 135Lys bovine enterokinase light chain; 112Ala, 134Lys bovine enterokinase light chain; 112Ala, 135Lys bovine enterokinase light chain and any such combinations including substitutions with other charged amino acids.
  • a bovine enterokinase light chain analogue which has improved solubility in a renaturation process relative to natural bovine enterokinase light chain.
  • a bovine enterokinase light chain analogue according to the invention has one or more surface oriented hydrophobic amino acids which have been mutated to hydrophilic, charged amino acids wherein improved solubility in a renaturation process relative to natural bovine enterokinase light chain is obtained.
  • surface oriented hydrophobic amino acids for substitution to hydrophilic charged amino acids are selected after aligning the bovine enterokinase light chain with other serine proteases and scanning the solvent-accessable surfaces through a computational 3D model of enterokinase.
  • refolding a bovine enterokinase light chain analogue according to the invention is known to the person skilled in the art.
  • refolding may be carried out by denaturation in urea, followed by oxidative refolding in glutathione or another re-dox environment.
  • a buffer (refolding buffer) is used during the refolding process.
  • the refolding buffer comprises urea.
  • the refolding buffer comprises between 0M and 2M urea.
  • the refolding buffer comprises between 0.5M and 2M urea, between 0M and 1.5M urea or between 0.5M and 1.5M urea.
  • the refolding buffer comprises about 1M urea.
  • the initial concentration of inclusion body may affect the refolding yield.
  • the concentration of inclusion body is between 1 and 4 mg/ml .
  • the thioredoxin (Trx) tag is removed during refolding, i.e. during dilution and incubation under refolding conditions. It has thus been found that refolding and activation may be obtained without addition of an activation enzyme.
  • the linker connecting the trx tag and the bovine enterokinase light chain analogue of the invention is removed by autocleavage. It has thus by the inventors surprisingly been found that the linker connecting the trx tag and the bovine enterokinase light chain analogue of the invention facilitates the refolding.
  • a bovine enterokinase light chain analogue according to the invention has the substitutions L134K and I135K, where the bovine enterokinase light chain analogue is more soluble during the renaturation process relative to wild type EK.
  • a bovine enterokinase light chain analogue according to the invention further has the substitution C112A.
  • a bovine enterokinase light chain analogue of the invention has full enterokinase activity compared to wild type bovine enterokinase.
  • a bovine enterokinase light chain analogue of the invention has a substantially equivalent functional or biological activity as wild type bovine enterokinase.
  • a bovine enterokinase light chain analogue has substantially equivalent functional or biological activities (i.e., is a functional equivalent) of the polypeptide having the amino acid sequence set forth as SEQ ID NO: 1 (e.g., has a substantially equivalent enteropeptidase activities).
  • Nucleic acid forms encoding enterokinase light chain analogues are also described herein.
  • Nucleic acids include genomic DNA (gDNA), complementary DNA (cDNA), synthetic DNA prepared by chemical synthesis as well as DNA with deletions or substitutions, allelic variants and sequences that hybridize thereto under stringent conditions as long as they encode enterokinase light chain analogues.
  • a nucleic acid comprising a polynucleotide sequence, and wherein said nucleic acid encodes a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue according to the invention.
  • the nucleic acid is operably linked to an inducible promoter.
  • a recombinant vector is provided which comprises the nucleic acid operably linked to the inducible promoter.
  • the inducible promoter is selected from a group consisiting of AraB, T7, trp, lac, tac.
  • a further embodiment of the invention provides a host cell comprising the recombinant vector comprising the polynucleotide sequence coding for the amino acid sequence of a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue according to the invention.
  • a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue according to the invention.
  • a further aspect of the invention provides the host cell comprising the recombinant vector comprising the polynucleotide sequence coding for the amino acid sequence encoding a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue according to the invention.
  • the host cell is selected from a group consisting of E.coli, B.subtilis, S.saccaromyces and A.oryzae.
  • enterokinase light chain The production of polypeptides, e.g., enterokinase light chain, is well known in the art.
  • the bovine enterokinase light chain analogue may for instance be produced by classical peptide synthesis, e.g., solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see, e.g., Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1999 .
  • the bovine enterokinase light chain analogue may also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the analogue and capable of expressing the bovine enterokinase light chain analogue in a suitable nutrient medium under conditions permitting the expression of the bovine enterokinase light chain analogue.
  • a method which comprises culturing a host cell containing a DNA sequence encoding the analogue and capable of expressing the bovine enterokinase light chain analogue in a suitable nutrient medium under conditions permitting the expression of the bovine enterokinase light chain analogue.
  • enterokinase in microorganisms such as, e.g., Escherichia coli and Saccharomyces cerevisiae are, e.g., disclosed in WO 94/16083 .
  • the bovine enterokinase light chain analogue is produced by expressing a DNA sequence encoding the bovine enterokinase light chain analogue in question or a precursor thereof in a suitable host cell by well known technique as disclosed in e.g. WO 94/16083
  • the bovine enterokinase light chain analogues of the invention may be recovered from the cell culture medium or from the cells.
  • the bovine enterokinase light chain analogues of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989 ).
  • chromatography e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion
  • electrophoretic procedures e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium s
  • the bovine enterokinase light chain analogues of the present invention are purified using anion exchange chromatography.
  • the anion exchange chromatography is followed by hydrophobic interaction chromatography.
  • the bovine enterokinase light chain analogues of the present invention are purified using Q HP anion exchange chromatography.
  • the Q HP anion exchange chromatography is followed by Phenyl FF hydrophobic interaction chromatography.
  • an improved process for production of a mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue is provided, wherein said method comprises the steps:
  • the invention provides a new recombinant process for production of mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue in E.coli in a very efficient and economic way.
  • mammalian enterokinase light chain analogue such as a bovine enterokinase light chain analogue in E.coli in a very efficient and economic way.
  • a bovine enterokinase light chain analogue according to the invention may e.g. be localized in the inclusion bodies of E. coli or in the secreted material of yeast. In one embodiment expression of enterokinase is localized in the inclusion bodies of E. coli.
  • E. coli Various strains of E. coli are useful as host cells for the production of non-glycosylated, homogeneous enterokinase activity are also well-known in the art.
  • a non-exclusive list of such strains includes E.coli B BL21 DE3, E.coli K12 W3110, MC1061, DH1, K803, HB101, JM101 and other K12 like strains.
  • other bacterial species may be used, including B. subtilis, various strains of Pseudomonas, other bacilli and the like.
  • yeast cells are also available as host cells for expression of the enterokinase activity of the present invention.
  • Yeast cells are especially useful as a host for pre/pro fusion to mature enterokinase. When expressed using a suitable yeast vector, the fusion is secreted by virtue of a signal peptide.
  • the bovine enterokinase light chain analogue of this invention When expressed in bacterial cells, it may be expressed intracellularly usually as inclusion bodies, or it may be secreted from bacterial cells in active form if a secretory signal is included. Where necessary or desired, as when reduced bioactivity is observed, the enterokinase activity may be obtained by conventional methods such as solubilization of protein in urea or guanidine HCI, followed by dilution to reduce the concentration of these reagents and treatment with oxidizing agents such as dithiothreitol or ss-mercapto ethanol to enhance refolding.
  • oxidizing agents such as dithiothreitol or ss-mercapto ethanol
  • the bovine enterokinase light chain analogues according to the invention are enzymatically active proteases which cleave specifically after a (Asp) 4 -Lys (DDDDK) sequence in various numbers of fused protein products between affinity tag and the mature protein.
  • the bovine enterokinase light chain analogues according to the invention have retained enzymatic activity
  • a process for preparing a bovine enterokinase light chain analogue in E. coli cells is obtained, wherein the E. coli cells are transformed with a plasmid carrying the bovine enterokinase light chain analogue gene and an inducible promoter by fermentation involving batch and fed batch stages and isolation and purification of the expressed protein from the cultures.
  • a refolding process for a bovine enterokinase light chain analogue according to the invention is obtained, wherein the expression of the enterokinase light chain analogue is in the form of inclusion bodies in recombinant E. coli.
  • denaturation followed by refolding in a redox system is used.
  • enterokinase light chain analogues of the invention may be used in a method for cleaving proteins having an enterokinase cleavage site, and especially fusion proteins having such a cleavage site engineered into their sequence.
  • the amounts needed are readily determined empirically by one skilled in the art.
  • fusion protein as used herein is meant to refer to a protein created through genetic engineering from two or more proteins or peptides.
  • a fusion protein can refer to a protein in which a Asp-Asp-Asp-Asp-Lys (D4K) sequence has been intentionally introduced for specific cleavage. Generally, cleavage of the fusion protein generates two polypeptides.
  • a fusion protein according to the invention can be a recombinant fusion protein.
  • a fusion protein can be generated, for example, from the addition of a vector-derived residue peptide at one terminus, for example the N-terminus, in addition to the amino acid sequence of the wild type protein of interest. In this way, for example, a recombinant fusion protein can be constructed to have Asp-Asp-Asp-Lys (D4K) cleavage site in the vector upstream joined to the protein of interest.
  • operably linked denotes herein a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of the polynucleotide sequence such that the control sequence directs the expression of the coding sequence of a polypeptide.
  • protease is intended to include any polypeptide/s, alone or in combination with other polypeptides, that break peptide bonds between amino acids of proteins.
  • proteolytic activity is meant to refer to the cleavage activity of a substrate by an enzyme.
  • the term refers to the enzymatic cleavage by enteropeptidases.
  • the term is meant to refer to the specific activity of a bovine enterokinase light chain analogue of the invention for Asp-Asp-Asp-Asp-Lys cleavage sites.
  • Non-specific proteolytic activity is meant to refer to cleavage activity that is not directed to a specific cleavage site.
  • Specific proteolytic activity is meant to refer to cleavage activity that is directed to a specific cleavage site.
  • a bovine enterokinase light chain analogue according to the invention is superior for cleavage of fusion proteins when compared to the bovine-derived two-chain form.
  • the enterokinase light chain analogue of the invention is incorporated as one of the fusion protein partners to yet another protein.
  • the fusion protein results in the release of additional enterokinase activity which in turn can catalyze many more proteolytic cleavages of fusion proteins.
  • large amounts of enterokinase activity can be produced from a fusion protein in an autocatalytic manner.
  • Another particular aspect of the invention teaches a method for cleavage of a protein containing an Asp-Asp-Asp-Asp-Lys cleavage site using any of the bovine enterokinase light chain analogues of the invention described herein, the method comprising contacting the protein with any of the bovine enterokinase light chain analogues of the invention, and wherein the contacting of the protein with the bovine enterokinase light chain analogue results in specific cleavage.
  • the protein is a fusion protein.
  • the fusion protein is a recombinant fusion protein.
  • the protein is bacterially produced.
  • the protein is a synthetic protein.
  • the invention teaches a method for the preparation of recombinant protein using any of the bovine enterokinase light chain analogues according to the invention as described herein, the method comprising providing a recombinant fusion protein containing a Asp-Asp-Asp-Asp-Lys cleavage site, and contacting the fusion protein with any of the bovine enterokinase light chain analogues of the invention, wherein contacting the recombinant fusion protein with the bovine enterokinase light chain analogue results in Asp-Asp-Asp-Asp-Lys specific cleavage and preparation of recombinant protein.
  • bovine enterokinase light chain analogues a production process for making bovine enterokinase light chain analogues.
  • the bovine enterokinase light chain analogues were fused to thioredoxin tag expressed as inclusion bodies in E.coli. After refolding and auto-activation, the active enterokinase light chain analogue was purified by Q HP anion exchange chromatography. Moreover, it was found that triple substitutions (C112A, L134K and I135K) of bovine enterokinase light chain (EK LM ), which improved the surface hydrophilic properties, increased the refolding yield 4 fold without loosing activity.
  • EK LM triple substitutions
  • the yield of purified enterokinase light chain analogue was 800mg/L from a culture of 4g/L, and the specific activity was determined as 5000 ⁇ 10 EU/mg.
  • our enterokinase light chain analogue production process provides a valuable tool for processing therapeutic fusion proteins and other fusion proteins.
  • the DNA sequence encoding the catalytic subunit of bovine enterokinase was amplified with the following primers:
  • These two primers contained Kpn I and EcoR I restriction enzyme sites, respectively.
  • the target fragment was introduced into pET32a (Novagen) from Kpnl and EcoRI site. Routine PCR reaction was performed using Pfu DNA Polymerase from Stratagene. The sequence of plasmid pET32a-EK L was confirmed by sequencing. Three substitution sites, i.e. C112A, L134K, 1135K were introduced by using QuikChange® XL Site-Directed Mutagenesis Kit from Stratagene with the primers:
  • Cells from a glycerol stock were inoculated on an EC1 plate grown overnight at 37°C, and washed with 0.9% sodium chloride (NaCl) to suspend the cells.
  • the culture was allowed to grow in a fermentor containing fermentation defined medium (FDM) at 37°C for 16 hrs, and induced with 1.0mM IPTG at an OD600 of 150, and then grown for 6 hours at 37°C before harvesting by centrifugation.
  • FDM fermentation defined medium
  • Trx-linker-EK L and Trx-linker-EK LM in E.coli BL21 were expressed in fed-batch fermentation. As shown in Fig.1 , no apparent leaky expression judged by SDS-PAGE was observed before IPTG induction. An induced band just above 43kD on SDS-PAGE by IPTG appeared, and it was confirmed by LC-MS that this band represented the target protein. Moreover, the expression level of the target protein was dependent upon the induction time. 4hrs or 6hrs of induction for Trx-linker-EK L and Trx-linker-EK LM by using fermentation defined medium (FDM), respectively gave acceptable expression, and ⁇ 4g/L of the target proteins was achieved.
  • FDM fermentation defined medium
  • lysis buffer (1:10, w/w) containing 20mM Tris, pH 8.0, and lysed by French press.
  • Inclusion bodies were sedimented at 20,000g for 1hr at 4°C, and then washed once by using lysis buffer.
  • the inclusion bodies were solublized to 3.2mg/ml in buffer containing 20mM Tris, 8M urea, pH8.0, 20mM DTT and incubated at 4°C for 3hrs. After centrifugation at 20,000g for 30min, the solublized EK (i.e.
  • Trx-linker-EK L and/or Trx-linker-EK LM was diluted 80 fold into refolding buffer containing 20mM Tris, 1M Urea, 1mM GSSG, 3mM GSH, pH 8.3 and incubated at 20°C for 24hrs.
  • the process scheme is shown in Fig.2 .
  • the inclusion bodies were solublized in the buffer containing 5-8M urea and 10-20mM DTT. It should be noted that the inclusion body concentration affected the refolding yield. It was found that the refolding yield of 4mg/ml Trx-linker-EK LM was 2 fold higher than that of 6mg/ml Trx-linker-EK LM ( Fig.3A ).
  • the refolding occurred by dilution.
  • the amount of purified enzyme from a fixed volume was also dependant upon the Trx linker EK concentration in the refolding buffer, and reached a maximum when Trx-linker-EK LM concentration was 120 ⁇ g/ml.
  • the auto-catalytic activation occurred concomitantly with the refolding process.
  • the active EK was liberated from Trx-linker-EK by the escape active EK, which specifically cleaved Trx tag off at DDDDK recognition site just before the mature EK.
  • the refolding and auto-catalytic activation process seemed optimal at48hrs ( Fig.4 ).
  • Considering the inhibition of EK by urea it was found that the refolding yield was largely reduced if above 2M urea in refolding buffer. Our result showed that 1M urea in refolding buffer was optimal ( Fig.5 ).
  • GSSG/GSH in the ratio 1:3 was found optimal and better than Cystine/cystein ( Fig.6 ).
  • the active EK after refolding and auto-activation was purified and concentrated by one step anion exchange chromatographic purification (QHP column, Fig.7A ). It was found that Trx tag was in P1, EK LM was mainly in P2 together with the impurity of Trx tag, and P3 contained trace amount of EK LM , which is confirmed by the activity assay shown in Fig. 7C . It should be noted that high purity EK LM (>90%) was obtained by further purification of P2 using hydrophobic interaction chromatography (HIC) ( Fig.7B ). Moreover, the enzymatic activity of each fraction was also assayed ( Fig.7C ), and pooled.
  • HIC hydrophobic interaction chromatography
  • Trx-linker-EK L the refolding yield was rather low beyond 40 ⁇ g/ml of Trx-linker-EK L during the refolding process (4.4% at 40 ⁇ g/ml), which made this process practically difficult. In other words, a huge holding tank is required to produce large amount of EK ( ⁇ 1,000g).
  • EK LM greatly improved the refolding yield, especially when EK LM concentration in refolding buffer was beyond 40 ⁇ g/ml, which is the bottle neck for the large scale production of EK L ( Fig.3A ).
  • Trx-linker-EK LM As shown in Fig.3A , at 40 ⁇ g/ml of Trx-linker-EK LM concentration in the refolding buffer, the refolding yield of Trx-linker-EK LM (17%) was 4 fold higher than that of Trx-linker-EK L (4.4%). Moreover, ⁇ 16mg of active EK LM could be purified from 1L refolding tank in which the EK LM concentration is 120 ⁇ g/ml.
  • EK L and EK LM The specific enzymatic activity between EK L and EK LM was compared as in Fig. 8 .
  • the triple substitutions of EK LM had no apparent effect on enzyme activity, which was evidenced by the fact that EK L and EK LM have similar bands on SDS-PAGE if loaded the same activity.
  • EK LM was quite stable if stored in buffer containing 20mM Tris, 200mM NaCl at -80°C or 4°C. No apparent degradation and decrease of activity were observed up to 3 months ( Fig.9 ).
  • the enzymatic activity was measured directly using a fluorogenic substrate, GDDDDK-Beta-naphthylamide.
  • the reaction was started with addition of 1ul sample into each well of Fluorescent 96 well plate containing 100ul of reaction buffer. After mixing for 10 seconds, the fluorescence was measured with Fluostar OPTIMA (excitation at 340nM and emission at 420nM).
  • the enzyme activity was defined by arbitrary unit (EU), which derived from slope*60/30,000, where the slope represented linear range.
  • TrxEK LM cell pellet was resuspended in 100ml of lysis buffer (20mM Tris, pH 8.0), and the cells were disrupted by using a homogenizer under a pressure of 30,000psi. After the supernatant was discarded, the IBs weighed 3.53g. The isolated IBs were resuspended in 70ml of solublization buffer (20mM Tris, 8M urea, pH8.0, 20mM DTT (freshly added)) and incubated at 4°C for 4hrs. The solublized samples were clarified by centrifugation.
  • 16ml of IBs solution was diluted into 500ml refolding buffer (20mM Tris, 1mM GSSG, 3mM GSH, 1M Urea, pH 8.0) and stirred at 20°C for 54hrs.
  • concentration of protein during refolding is 60 ⁇ g/ml.
  • the elution fractions with highest enzyme activity were combined resulting in a pool volume of 30ml and total enzyme activity of 14,100EU.
  • the protein amount was 2.82mg.
  • Trx-linkerEK LM cell pellet was resuspended in 1000ml of lysis buffer (20mM Tris, pH 8.0), and the cells were disrupted by using a homogenizer under a pressure of 30,000psi. After the supernatant was discarded, the IBs weighed 22g and were washed by 1000ml of 20mM Tris, pH 8.0 once. After wash, the IBs solution was divided into 6 bottles for centrifugation. After the supernatant was discarded, 41ml of solublization buffer (20mM Tris, 8M urea, pH8.0, 20mM DTT (freshly added)) was added into one bottle and incubated at 4°C for 3hrs. The solublized IBs were clarified by centrifugation and the final volume was 43ml.
  • solublization buffer 20mM Tris, 8M urea, pH8.0, 20mM DTT (freshly added)
  • the enzyme activity of elution fractions 18-23 is higher than the other fractions through activity test.
  • the elution fractions with highest enzyme activity were combined resulting in a pool volume of 30ml and total enzyme activity of 24,900EU.
  • the protein amount was 4.98mg.
  • EK LM protein 2.82mg was produced from 0.5L of refolding solution when using TrxEK LM when the protein concentration was 60 ⁇ g/ml during refolding, whereas 4.98mg of EK protein was produced from Trx-linker-EK LM version under the same conditions.
  • Trx-linker-EK LM version 3.82mg was produced from Trx-linker-EK LM version under the same conditions.
  • Example 6 Components optimization of the refolding buffer
  • the inclusion bodies were solubilized to 7.3mg/ml in the buffer containing 20mM Tris, 8M urea, pH8.0, 20mM DTT, and then the solubilized Trx-linker-EK LM was added into the optimized refolding buffer containing certain additive by 20-fold dilution. The mixture was incubated at 4°C for 20hrs and the amount of correctly refolded Trx-linker-EK LM was quantified by protease activity assay as described in Example 4.

Claims (7)

  1. Rinder-Enterokinase-Leichtkettennalogon, umfassend eine in SEQ ID NO: 1 dargestellte Aminosäuresequenz, wobei das Analogon die Substitutionen C112A, L134K und I135K umfasst und das Analogon weniger als 10 Aminosäuremodifikationen relativ zu SEQ ID NO: 1 aufweist und das Analogon Enterokinase-Protease-Aktivität aufweist.
  2. Verfahren zum Erhalten einer verbesserten Löslichkeit in einem Renaturierungsprozess eines Enterokinase-Leichtkettenanalogons, umfassend den Schritt des Mutierens hydrophober Aminosäuren von Leichtketten-Wildtyp-Rinder-Enterokinase von SEQ ID NO: 1 zu hydrophilen Aminosäuren und gegebenenfalls Mutieren anderer Aminosäuren von Leichtketten-Wildtyp-Rinder-Enterokinase, wobei die der Mutation unterworfenen hydrophoben Aminosäuren auf der Fläche von gefalteter Leichtketten-Wildtyp-Rinder-Enterokinase vorhanden sind, das Analogon die Substitutionen C112A, L134K und I135K umfasst, das Analogon relativ zu SEQ ID NO: 1 weniger als 10 Aminosäuremodifikationen umfasst und das Analogon Enterokinase-Protease-Aktivität aufweist.
  3. Verfahren zum Herstellen eines Rinder-Enterokinase-Leichtkettenanalogons, wobei das Rinder-Enterokinase-Leichtkettenanalogon ein Analogon nach Anspruch 1 ist, und wobei das Verfahren die Schritte umfasst:
    a) Kultivieren der Wirtszellen in einem Wachstumsmedium, das einen Induktor umfasst, wobei die Wirtszellen eine Polynukleotidsequenz umfassen, welche die Aminosäuresequenz des Enterokinase-Leichtkettenanalogons codiert;
    b) Wiedergewinnen der Zellen mit dem Enterokinase-Leichtkettenanalogon in Einschlusskörpern;
    c) Auflösen und Rückfalten des Enterokinase-Leichtkettenanalogons; und
    d) Reinigen des Enterokinase-Leichtkettenanalogons.
  4. Verfahren zur rekombinanten Herstellung eines Peptids oder Proteins in einer Bakterien- oder Hefewirtszelle, umfassend:
    a) Exprimieren eines Fusionsproteins, welches das herzustellende Peptid oder Protein umfasst, in Hefe oder Bakterien;
    b) Spalten des Fusionsproteins mit dem Rinder-Enterokinase-Leichtkettenanalogon nach Anspruch 1; und
    c) Isolieren des hergestellten Peptids oder Proteins.
  5. Verfahren zur rekombinanten Herstellung eines Peptids oder Proteins nach Anspruch 4, wobei das in Schritt a) exprimierte Fusionsprotein ferner eine Asp-Asp-Asp-Asp-Asp-Lys-Spaltstelle umfasst.
  6. Verfahren zur rekombinanten Herstellung eines Peptids oder Proteins nach einem der Ansprüche 4 bis 5, wobei die Wirtszelle E. coli ist.
  7. Verfahren zur rekombinanten Herstellung eines Peptids oder Proteins nach einem der Ansprüche 4 bis 6, wobei das herzustellende Peptid oder Protein ein GLP-1-Peptid ist.
EP12816050.4A 2011-12-23 2012-12-20 Modifizierte leichte enterokinasekette Active EP2794875B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011002169 2011-12-23
PCT/EP2012/076372 WO2013092855A1 (en) 2011-12-23 2012-12-20 Modified enterokinase light chain

Publications (2)

Publication Number Publication Date
EP2794875A1 EP2794875A1 (de) 2014-10-29
EP2794875B1 true EP2794875B1 (de) 2020-07-22

Family

ID=47561561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12816050.4A Active EP2794875B1 (de) 2011-12-23 2012-12-20 Modifizierte leichte enterokinasekette

Country Status (5)

Country Link
US (1) US9611466B2 (de)
EP (1) EP2794875B1 (de)
JP (1) JP6138151B2 (de)
ES (1) ES2819288T3 (de)
WO (1) WO2013092855A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982287B2 (en) * 2013-12-17 2018-05-29 Novo Nordisk A/S Enterokinase cleavable polypeptides
WO2017118752A1 (en) * 2016-01-07 2017-07-13 Novo Nordisk A/S Modified enterokinase light chain and its preparation method
CN109136209B (zh) * 2018-07-18 2021-07-06 上海雅心生物技术有限公司 肠激酶轻链突变体及其应用
CN114807101B (zh) * 2022-06-20 2022-09-16 北京惠之衡生物科技有限公司 包含牛肠激酶轻链蛋白的融合蛋白及其表达载体和重组工程菌
CN116064491A (zh) * 2022-06-20 2023-05-05 北京惠之衡生物科技有限公司 牛肠激酶轻链蛋白突变体及其重组融合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432787D1 (de) 1993-01-15 2003-07-10 Inst Genetics Llc Klonierung von Enterokinase und Verfahren zu deren Verwendung
KR19990073067A (ko) 1999-03-13 1999-10-05 문정복 레일천공기
KR100507980B1 (ko) 2002-06-18 2005-08-17 프로테온 주식회사 엔테로키나제 경사슬의 아미노말단 또는 카르복실말단이 변형된 재조합 엔테로키나제
CN1214107C (zh) 2002-07-26 2005-08-10 刘建宁 一种具有高活性和高稳定性的肠激酶轻链变体
CN1869236A (zh) 2005-05-24 2006-11-29 上海新生源医药研究有限公司 一种重组牛肠激酶的生产方法
WO2008136014A1 (en) 2007-05-07 2008-11-13 Usv Limited Cloning and expression of enterokinase and its process for production
CN101613687A (zh) 2007-05-11 2009-12-30 上海张江生物技术有限公司 重组牛肠激酶、其制备方法及用途
CN102061302B (zh) 2010-11-26 2012-07-04 扬子江药业集团北京海燕药业有限公司 肠激酶轻链基因的合成及其表达产物的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
ES2819288T3 (es) 2021-04-15
EP2794875A1 (de) 2014-10-29
JP6138151B2 (ja) 2017-05-31
US9611466B2 (en) 2017-04-04
US20150064744A1 (en) 2015-03-05
JP2015502167A (ja) 2015-01-22
WO2013092855A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
Choi et al. Recombinant enterokinase light chain with affinity tag: expression from Saccharomyces cerevisiae and its utilities in fusion protein technology
EP2794875B1 (de) Modifizierte leichte enterokinasekette
JP4538501B2 (ja) ポリペプチドのｃ末端修飾
CN109486800B (zh) 一种新型赖氨酰肽链内切酶及其制备方法
US20160083713A1 (en) Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
WO2012104099A1 (en) Process for the production of recombinant trypsin
US7892787B2 (en) Method for production of recombinant growth hormone in form of hybrid protein
CN109439643B (zh) 一种新型赖氨酸特异性内切酶及其制备方法
ES2754271T3 (es) Polipéptidos escindibles por enteroquinasa
CN103998606B (zh) 修饰的肠激酶轻链
WO2017118752A1 (en) Modified enterokinase light chain and its preparation method
US11267863B2 (en) N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same
Liu et al. Large scale preparation of recombinant human parathyroid hormone 1–84 from Escherichia coli
CN112824527A (zh) 人工设计的赖氨酰内切酶及编码序列和发酵方法
US20090258394A1 (en) Method for the production of high-level soluble human recombinant interferon alpha in e. coli and vectors useful for such a production
US7662935B2 (en) Processing of peptides and proteins
Yang et al. High-level production of a candidacidal peptide lactoferrampin in Escherichia coli by fusion expression
Su-Xia et al. Cloning and expression of a new rat procarboxypeptidase B gene in Escherichia coli and purification of recombination carboxypeptidase B
Song et al. Engineered recombinant enteropeptidase catalytic subunit: effect of N-terminal modification
EP1841862B1 (de) Ubp1-proteasemutante sowie ihre codierende sequenz, deren anwendungen und heterogenes proteinexpressionssystem
CN111197041B (zh) 制备青鳉鱼肠激酶活性亚基的方法、其产物和用途
Son et al. Effects of β-mercaptoethanol and hydrogen peroxide on enzymatic conversion of human proinsulin to insulin
KR100562873B1 (ko) 인간 인슐린 발현 플라스미드 및 이를 이용한 인간인슐린의 제조 방법
KR101002166B1 (ko) 재조합형 ｇｓｔ 융합 단백질의 정제방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160224

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTG Intention to grant announced

Effective date: 20191121

INTG Intention to grant announced

Effective date: 20191203

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTG Intention to grant announced

Effective date: 20200103

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200227

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012071393

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1293419

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1293419

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201022

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201022

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201023

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201123

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201122

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2819288

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012071393

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

26N No opposition filed

Effective date: 20210423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221122

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230102

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231124

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231122

Year of fee payment: 12

Ref country code: DE

Payment date: 20231121

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240102

Year of fee payment: 12